Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.

NCT00551031 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00551031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00551031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
November 30, 2008
Enrollment
2,098 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, myxovirus infection